Journal: Current Oncology

Article Title: Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective

doi: 10.3747/co.25.4031

Figure Lengend Snippet: PD-L1 testing methods

Article Snippet: 22C3 SP263 SP142 Rimm et al., 2017 30 (Bristol–Myers Squibb, NCCN) 28-8 90 list-behavior=simple prefix-word= mark-type=none max-label-size=0 ■ SP142 was an outlier, detecting significantly less PD-L1 expression in tumour cells and immune cells.

Techniques: Amplification

Journal: Current Oncology

Article Title: Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective

doi: 10.3747/co.25.4031

Figure Lengend Snippet: PD-L1 comparability studies in non-small-cell lung cancer

Article Snippet: 22C3 SP263 SP142 Rimm et al., 2017 30 (Bristol–Myers Squibb, NCCN) 28-8 90 list-behavior=simple prefix-word= mark-type=none max-label-size=0 ■ SP142 was an outlier, detecting significantly less PD-L1 expression in tumour cells and immune cells.

Techniques: Staining, Expressing

Journal: Breast Cancer Research and Treatment

Article Title: Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

doi: 10.1007/s10549-021-06193-9

Figure Lengend Snippet: Clinical and pathological characteristics of SP142 PD-L1-positive TNBC. a The PD-L1 positive rate according to SP142 expression was 28.9% (43 of 149). b Representative images for PD-L1-positive and -negative tumors in high-power fields (× 400 magnification). c Left: SP142 PD-L1 percent positivity partitioned by TNBCtype (immunomodulatory [IM], basal-like 1 [BL1], basal-like 2 [BL2], luminal-androgen receptor [LAR], mesenchymal [M], mesenchymal stem-like subtypes [MSL], and unspecified [UNS]). The rate of PD-L1-positive tumors was significantly higher in the IM subtype; the IM subtype had the highest rate of PD-L1 positivity (57.1%), whereas the other subtypes had PD-L1-positivity rates of 10–30% (Chi-square test). Right: PD-L1-positivity rate was not significantly different according to the PAM50 subtype (Chi-square test). d PD-L1-positive TNBC had significantly higher mean CD8(+) percentage count (Mann–Whitney U test). e PD-L1-positive TNBC had higher mean of TIL counts compared to PD-L1-negative TNBC (Mann–Whitney U test). f Recurrence-free survival was significantly prolonged in PD-L1-positve TNBC than in PD-L1-negative TNBC (log-rank test)

Article Snippet: PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test) We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. c).

Techniques: Expressing, MANN-WHITNEY

Journal: Breast Cancer Research and Treatment

Article Title: Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

doi: 10.1007/s10549-021-06193-9

Figure Lengend Snippet: An RNA expression-based SP142 gene signature. a PD-L1 mRNA expression in breast tumor samples partitioned by SP142 PD-L1 status (Mann–Whitney U test). b A heat-map clustering breast tumors with 21 genes of the “Lymphocyte Mediated Immunity” signature. The rows indicate individual genes, and the columns indicate each sample. PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test)

Article Snippet: PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test) We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. c).

Techniques: RNA Expression, Expressing, MANN-WHITNEY

Journal: Breast Cancer Research and Treatment

Article Title: Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

doi: 10.1007/s10549-021-06193-9

Figure Lengend Snippet: The Cox regression hazard model with SP142 signature and stage

Article Snippet: PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test) We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. c).

Techniques:

Journal: Breast Cancer Research and Treatment

Article Title: Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

doi: 10.1007/s10549-021-06193-9

Figure Lengend Snippet: Clinical value of SP142 signature in TNBC. a In the Madrid cohort, (NCT01560663), pathologic complete response (pCR) rate was higher in the SP142 signature top two-thirds group (Chi-square test). b SP142 signature score was significantly higher in the pCR group than in non-pCR group (unpaired T -test). c Overall Survival (OS) in TNBC from SCAN-B, with patients classified by SP142 signature and chemotherapy treatment status., Patients in the SP142 signature top two-thirds group that received chemotherapy had better OS (the log-rank test). The interaction test between chemotherapy treatment and dichotomized SP142 signature status was significant ( P interaction = 0.026). d Disease-free, and e overall survival in TNBC patients of the METABRIC cohort. The SP142 signature top two-thirds group had significantly better prognosis (log-rank test)

Article Snippet: PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test) We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. c).

Techniques:

Journal: Breast Cancer Research and Treatment

Article Title: Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

doi: 10.1007/s10549-021-06193-9

Figure Lengend Snippet: Immunologic characterization for SP142 signature in the TNBC of TCGA. a Left: The lymphocyte-infiltrating signature score was significantly higher in the top two-thirds SP142 signature group than in the bottom one-third group (Mann–Whitney U test). Tumor mutational burden ( middle ) and total neoantigen count ( right ) did not significantly differ between the top two-thirds and bottom one-third SP142 signature groups (Mann–Whitney U test). b The SP142 signature score shows strong correlation with the lymphocyte-infiltration score, but not with correlated with total mutation burden (TMB) or total neoantigen count. TMB and total neoantigen were also correlated (Pearson’s R -test). The numbers in the graph indicate Spearman rank correlation coefficients. c Heat-map displaying immune-related gene signatures with > fourfold increase between SP142 signature top two-thirds and bottom one-third groups (SAM analysis)

Article Snippet: PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test) We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. c).

Techniques: MANN-WHITNEY, Mutagenesis

Journal: Breast Cancer Research and Treatment

Article Title: Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer

doi: 10.1007/s10549-021-06193-9

Figure Lengend Snippet: SP142 signature in other malignancies treated with immune check-point inhibitors (ICIs). a – d In metastatic urothelial carcinoma patients treated with atezolizumab, a SP142 signature score in patients partitioned by treatment response ( PD progressive disease, SD stable disease, PR partial response, CR = complete response). The complete response (CR) group showed the highest mean SP142 signature score (one-way ANOVA test). b Response rates in patients partitioned by SP142 signature scores tertiles. The CR rate was higher, while PD was lower in top one-third than in either middle or bottom one-third groups (the Chi-square test). c SP142 signature score in the subsets of patients by VENTANA SP142 assay classification (IC0 = PDL1 expressing immune cells < 1%, IC1 (≥ 1% and < 5%), IC2/3 (≥ 5%)). SP142 score showed an increasing pattern according to the IC groups (one-way ANOVA test, P < 0.001; unpaired T -test between IC0 and IC1, P < 0.0001; unpaired T -test between IC1 and IC2/3, P < 0.0001). d Overall survival (OS) of patients grouped with the top one-third SP142 signature score versus the bottom two-thirds (log-rank test). e , f In melanoma patients treated with immune-check point inhibitors, progression-free ( e ), and overall survival ( f ) are significantly better for the group of patients in the top two-thirds of SP142 signature score relative to the lowest one-third group (log-rank test)

Article Snippet: PD-L1 IHC status and relative PD-L1 mRNA expression are denoted for each sample above. c SP142 signature was significantly higher in PD-L1-positive tumors (Mann–Whitney U test). d The proportion of PD-L1 positive patients in the top two-thirds SP142 signature group is significantly higher than in the bottom one-third group (Chi-square test). e The top two-thirds SP142 signature group had a superior recurrence-free survival compared to the bottom one-third SP142 signature group (log-rank test) We next calculated a SP142 signature score in our 149 subjects and found that, as expected, the mean score was significantly higher in PD-L1+ TNBC than in PD-L1-negative (Fig. c).

Techniques: Expressing